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Abstract
Background: The incidence of thyroid cancer in Korea has increased by about 25 % every year for the past 10 years.
This increase is largely due to a rising incidence in papillary thyroid cancer, which is associated with an overdiagnosis
of small tumors that may never become clinically significant. This study was conducted to explore Korean women’s
understanding of overdiagnosis and to investigate changes in screening intention in response to overdiagnosis
information.
Methods: Focus group interviews were conducted among women of ages 30–69 years, who are commonly targeted
in Korea for cancer screening. Women were divided into four groups according to thyroid cancer screening history and
history of thyroid disease. Of 51 women who were contacted, 29 (57 %) participated in the interviews.
Results: Prior awareness of thyroid cancer overdiagnosis was minimal. When informed about the risks of overdiagnosis,
the participants were often surprised. Overcoming initial malcontent, many women remained skeptic about
overdiagnosis and trusted in the advice of their physicians. Meanwhile, some of the study participants found
explanations of overdiagnosis difficult to understand. Further, hearing about the risks of overdiagnosis had
limited impact on the participants’ attitudes and intentions to undergo thyroid cancer screening, as many
women expressed willingness to undergoing continued screening in the future.
Conclusion: A large majority of Korean women eligible for and had undergone thyroid cancer screening were
unaware of the potential for overdiagnosis. Nevertheless, overdiagnosis information generally had little impact on
their beliefs about thyroid cancer screening and their intentions to undergo future screening. Further research is
needed to determine whether these findings could be generalized to the wider Korean population.
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Background
Over the last 10 years, the incidence of thyroid cancer in
Korea has increased every year by about 25 %, such that
thyroid cancer now leads as the most common type of
cancer in women across the nation [1]. In fact, more
than 40,000 people were diagnosed with the disease in
2011. More specifically, the proportion of small (<1 cm)
tumors detected has increased significantly from 6 % in
1962 to 43 % in 2009; meanwhile, mortality rates for
thyroid cancer have remained constant [2]. According to
estimates by GLOBOCAN 2012, the incidence of thyroid
cancer among Korea women (age standardized rate, 88.6
per 100,000 population) is more than 18 times greater
than that for the UK and 4.4 times that for the US [3].
This increase in the incidence of thyroid cancer in Korea
is largely due to a rising incidence in papillary thyroid can-
cer (PTC), which is associated with an excellent prognosis
and a 10-year survival rate of 98.6 % [4]. PTC is the most
common subtype of thyroid cancer, accounting for 90 % of
all thyroid cancer occurrences in Korea, and its incidence
has increased annually by 25.1 % in men and 23.7 % in
women from 1997 through 2011 [5]. Nevertheless, despite
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favorable long-term survival, PTC is associated with sig-
nificant morbidity and societal burden. While studies have
yet to outline definitive reasons for increases in thyroid
cancer incidence, some have suggested that the apparent
increases in thyroid cancer do not represent a true in-
crease in disease but rather result from a large reservoir
of undiagnosed PTC combined with overdiagnosis of small
tumors that will never become clinically significant [6–8].
Although thyroid-cancer screening is not included in
the National Cancer Screening Program in Korea, health-
care providers frequently choose to offer opportunistic
screening for thyroid cancer with ultrasonography as an
inexpensive add-on for about 30 to $50. Moreover, the
offices of many general practitioners are equipped with
ultrasonography machines for which to scan the thyroid
for cancer. Interestingly, a previous report in Korea noted
a strong correlation between thyroid cancer screening
rates and the incidence of thyroid cancer by region [6].
While generally positive, screening for the early detec-
tion of cancer can lead to overdiagnosis, resulting in the
overtreatment of inconsequential disease and thereby
unwarranted physical and emotional harm [9]. Despite
the harms of overdiagnosis, little is known about the
public’s understanding of overdiagnosis or how overdiag-
nosis information may affect one’s decision to undergo
screening. Notwithstanding, recent qualitative studies
found that information on overdiagnosis was difficult for
screening-eligible women to understand and was often
surprising [10, 11].
Thus, we conducted a qualitative study to assess re-
sponses to information about overdiagnosis in thyroid
screening among Korean women. The study was designed
to highlight their understanding of information on overdi-
agnosis, as well as to investigate changes in their inten-
tions to undergo screening in the future in response to
overdiagnosis information.
Methods
Study design and setting
In the present study, we conducted focus group interviews
to explore existing knowledge of and experiences with
thyroid cancer screening among Korean women. We also
attempted to discover how women integrated information
about overdiagnosis with their existing understanding of
thyroid cancer screening and how they might utilize the
information when deciding whether or not to undergo
continued screening. Collecting data through focus
groups, rather than individual interviews, allowed partici-
pants to raise and discuss relevant points beyond those
anticipated by the researchers [12]. All participants pro-
vided written consent prior to participation in the inter-
views. This study was approved by the Institutional
Review Board of the National Cancer Center, Korea (IRB
No.: NCCNCS08129).
Recruitment
We conducted four focus group interviews with women
of ages 30–69 years, who are commonly targeted for can-
cer screening. In order to ensure the homogeneity within
each group, we included women who had the same experi-
ences with thyroid cancer screening. Based on their histor-
ies of thyroid cancer screening and thyroid disease, the
following four groups were formed: Group 1, women who
had never undergone thyroid cancer screening; Group 2,
women who had undergone thyroid cancer screening
(ultrasonography test) within the last 24 months with
negative results; Group 3, women with benign thyroid nod-
ules, for which they visited the hospital regularly for a
check-up; and Group 4, women who underwent a thyroid-
ectomy to remove all or part of the thyroid gland after be-
ing diagnosed with thyroid cancer. While each individual
focus group was characteristically homogeneous, the differ-
ences between the groups were large enough to allow for
contrasting opinions.
Participants were recruited at the Center for Cancer
Prevention & Detection with the National Cancer Center,
Korea via advertisements posted throughout the National
Cancer Center Hospital. The advertisement described our
search for women who would be willing to participate in a
focus group interview to discuss overdiagnosis and thyroid
cancer screening, along with information about the pur-
pose of the study, the interview duration, selection criteria,
and a financial incentive (about 70 US dollars) for partici-
pation. Among volunteers who responded to the advertise-
ment, we primarily looked for women who fulfilled criteria
for inclusion in one of the four groups. We then chose
prospective participants after considering the age distribu-
tion of each group and on a first-come, first-served basis.
The focus group sessions were scheduled to best accom-
modate the availability of the participants; we proposed
four alternate interview days to 51 women who were finally
contacted. A total of 29 (57 %) participated in the inter-
view. In this study, each group comprised five to ten
women: typically, the ideal size of a focus group for most
noncommercial topics is five to eight participants [13].
Data collection
The interviews were conducted in August 2014 in a con-
ference room at the National Cancer Center, Korea, and
were facilitated by an experienced qualitative researcher,
with a second researcher acting as an observer. To en-
sure data authenticity, we selected a neutral “third party”
interviewer to conduct the interviews. The interviewer
was given our expectations for the study, preconceptions,
values, and orientation information, including any theoret-
ical commitments. Also, to prevent questions from being
asked in a way that may lead the participants to answer in
a particular manner, we provided the interviewer an inter-
view guide (Table 1). In designing the discussion guide,
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emphasis was placed on constructing open-ended, non-
directive questions and using a funneling approach,
with questions moving from the general to the more
focused.
Before starting the focus group discussion, participants
were asked to complete a short questionnaire assessing
sociodemographic characteristics (age, education, and in-
come level), family history of cancer, and previous history
of thyroid cancer screening among family members. To
open the discussion, in accordance with the focus group
interview guide (Table 1), participants were invited to dis-
cuss their own experiences with deciding whether or not to
undergo thyroid cancer screening. They were then asked to
read information concerning thyroid cancer screening,
which included a statement on overdiagnosis (“Screening
can discover treatable cancers that may have otherwise
gone unnoticed during your lifetime.”) After briefly
reading aloud additional information on overdiagnosis,
women were asked to discuss how this information
might affect their views of thyroid cancer screening.
Group discussions were digitally recorded and tran-
scribed verbatim.
Analysis
In the present study, we conducted a thematic analysis,
aiming to identify a set of main themes that captured the
diverse views and feelings expressed by the participants.
Verbatim transcripts were analyzed thematically. Two
researchers read all of the transcripts independently and
generated initial codes. These were then collated into
potential themes. Using constant comparison, we strived
to highlight similarities and differences in the data, as well
as coding within and across transcripts. Meeting regularly
to discuss the framework with which to interpret the data,
we compared parts of the data with the rest as a whole,
establishing analytical categories and selecting key themes.
In this study, two researchers coded a total of 812 verba-
tim transcripts. The two researchers finally selected 40
transcripts to be coded for inclusion in the framework.
Among these 40 transcripts, 33 were given the same codes




The demographic characteristics of all 29 individuals
who agreed to participate in this study are described in
Table 2. Among the participants, those in their 50s were
most common, followed by those in their 30, 40, and
60s. According to household income, 40 % of participants
in Group 1, those who had never undergone thyroid
cancer screening, earned less than 2000 US dollars per
month. While the proportion of those who responded
that they knew of a family member or acquaintance
who had thyroid cancer was high for the entire study
population, Group 1 participants more often responded
that they did not know of anyone close to them with
thyroid cancer.
Knowledge of thyroid cancer and thyroid cancer
screening
When asked about thyroid cancer and thyroid cancer
screening, as well as where they received their informa-
tion thereon, the majority of the participant responded
Table 1 Focus group interview guide and key discussion
questions
ㆍSelf-assessment of health and health behavior including cancer
screening
ㆍOverall knowledge of cancer, cancer prevention, and screening
ㆍKnowledge of thyroid cancer and thyroid cancer screening
ㆍPerceptions of overdiagnosis
ㆍProvide information on thyroid cancer screening and overdiagnosis
- Thyroid cancer screening incidence, mortality, and survival rates in
Korea: incidence has increased 15-fold over the past two decades;
the most commonly diagnosed cancer in women. Almost all newly
identified thyroid cancers are tiny papillary thyroid tumors (very
slow-growing, highly unlikely to go on to cause symptoms, and
much less death). Mortality rates have not budged over the past
20 years; 5-year relative survival rate is almost 100 %.
- Introduction to thyroid cancer screening: test with
ultrasonography costs 30 to 50 USD
- Definition of overdiagnosis: diagnosis of thyroid cancer that may
not go on to cause symptoms or death in your life time
- Harms of overdiagnosis: unnecessary effects of thyroidectomy: a
lifelong calcium-metabolism condition; vocal cord paralysis, etc.
ㆍPros and cons of thyroid cancer screening and changes in intentions
to undergo screening in the future
ㆍInformation needs for thyroid cancer screening
Table 2 Characteristics of the participants
Group 1 Group 2 Group 3 Group 4 Total
(n = 10) (n = 7) (n = 5) (n = 7) (n = 29)
Age (years)
30–39 2 (20.0) 3 (42.8) 1 (20.0) 3 (42.8) 9 (31.0)
40–49 3 (30.0) 1 (14.3) 2 (40.0) 1 (14.3) 7 (24.1)
50–59 3 (30.0) 3 (42.8) 2 (40.0) 2 (28.6) 10 (34.5)
60–69 2 (20.0) - - 1 (14.3) 3 (10.3)
Monthly household income (US $)
≤1,999 4 (40.0) - - 2 (28.6) 6 (20.7)
2,000–3,999 3 (30.0) - 3 (60.0) 2 (28.6) 8 (27.6)
4,000–6,999 2 (20.0) 5 (71.4) 1 (20.0) 2 (28.6) 10 (34.5)
≥7,000 1 (10.0) 2 (28.6) 1 (20.0) 1 (14.3) 5 (17.2)
Family history of thyroid cancer (or a friend diagnosed with thyroid
cancer)
Yes 4 (40.0) 6 (85.7) 3 (60.0) 6 (85.7) 19 (65.5)
No 6 (60.0) 1 (14.3) 2 (40.0) 1 (14.3) 10 (34.5)
Park et al. BMC Cancer  (2015) 15:858 Page 3 of 8
saying they thought thyroid cancer is a slowly developing
cancer with a higher survival rate, and thus, did not
regard it as serious. This perception was especially com-
mon among Group 1 and Group 2 participants: 81 %
recognized thyroid cancer as a non-fatal cancer, whereas
15 % of women in Group 3 and Group 4 thought it was
likely to develop into severe disease and to negatively
affect their quality of life.
“While I have seen people with thyroid cancer, I heard
that it grows slowly and that it can be cured without
difficulty, if it is found early enough. I do not take it to
be serious.”
“I only know that the majority of thyroid cancer
patients are women and that Korea has a higher
incidence thereof.”
Meanwhile, many of the participants reported knowing
very little about the function and location of the thyroid,
as well as risk factors for thyroid cancer, particularly par-
ticipants in Groups 1 and 2. Only 18 % of women in
Group 1 and Group 2 who had a thyroid cancer patient in
their family knew the function and location of the thyroid,
as well as risk factors for thyroid cancer. However, 100 %
of women in Group 3 and Group 4 knew extensive infor-
mation about thyroid cancer, except for the adverse effects
of thyroid surgery.
“I have no idea where the thyroid is or what function
it serves.” (Group 2 participant)
“I suspect that thyroid cancer may result from
improper self-management, such as bad habits or a
lack of exercise.” (Group 2 participant)
“Since the thyroid controls the hormone system, I would
guess that stress might be the cause [of thyroid cancer],
but I do not know very well.” (Group 1 participant)
Regarding where the participants had received their in-
formation on thyroid screening, 51 % of participants re-
ported hearing about it from the media (e.g., internet
and TV); however, none responded that they learned
about it from their doctors. Group 1 participants typic-
ally reported knowing nothing about thyroid cancer
screening procedures. Many of the participants who had
experiences with screening stated they had received in-
formation about thyroid cancer screening during routine
health check-ups; their motivations to undergo screening
primarily stemmed from a family history of cancer (10 %
of the participants) or recommendations from close
acquaintances (10 % of the participants), rarely from
observable symptoms (3 % of the participants).
Perceptions of overdiagnosis
During the interviews, we particularly noted controversy
among the participants regarding the potential dangers
of overdiagnosis in thyroid cancer screening. We have
outlined the participants’ reactions to the following state-
ment regarding overdiagnosis in thyroid cancer: “Recently,
cases of thyroid cancer are rapidly increasing, largely due
to overdiagnosis from cancer screening. Overdiagnosis is
the diagnosis of disease that will never cause symptoms or
death during a patient’s lifetime, and may lead to treat-
ments that are of no benefit and perhaps harmful.”
The participants’ reactions to this statement were
summarized into five main types: confusion, denial, mal-
content, trust in physicians, and indifference.
(a) Confusion: The majority of the participants (90 %)
stated that did not entirely grasp the meaning of
overdiagnosis, and 15 % of them responded that the
concept thereof was difficult to comprehend. All of
the participants in Groups 1 and 2 expressed such
confusion.
“I have never heard about overdiagnosis. Despite
learning about it in this interview, I still do not fully
understand it.”
“On TV, many programs talk about whether or not
one should undergo thyroid screening, seek treatment,
etc. The differing opinions are very confusing and
make it harder to understand what to do.”
“For the elderly, it [overdiagnosis] is difficult to
understand and complicates making a decision.”
(b) Denial: Some of the participants (17 %) considered
thyroid cancer as a major cancer type, and they
denied overdiagnosis as a serious issue. These
participants expressed a strong belief that cancer
screening for preventive purposes could not be
adverse to one’s health. This was particular apparent
among Group 3 participants, those with benign
thyroid nodules, who communicated complete trust
in their doctors to watch over their health.
“The word ‘overdiagnosis’ is inappropriate. I think
finding disease early and seeking timely treatment is
very important. [We can ensure our health through
screening.]”
“For preventive purposes, early discovery of disease is
necessary, though it may cause overdiagnosis.”
“People have stated that thyroid cancer is unnecessarily
overdiagnosed; however, I do not agree. Every single
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disease must be identified. Whether or not one should be
treated is up to the individual, but just finding disease is
not unreasonable.”
“Is it not natural to seek treatment or surgery if there
is a defect? I do not think it is too excessive.”
“I heard that the National Health Insurance Service
plans to cut reimbursement for thyroid cancer
diagnostic and treatment tests to save money. I think
that is why the media frequently negatively reports on
overdiagnosis from thyroid cancer screening. This
whole thing is a conspiracy”
(c) Malcontent: Overall 15 % of women voiced
displeasure with healthcare professionals concerning
a lack of information on overdiagnosis of thyroid
cancer. Those who had undergone screening were
surprised and annoyed that they were not informed
about overdiagnosis prior to screening and
treatment. Additionally, women were generally more
worried about overtreatment than overdiagnosis.
Nearly 10 % of women even suspected that
physicians may encourage thyroid cancer screening
for their own financial benefit.
“I have heard about overdiagnosis. I heard it from my
acquaintances, also from the internet. Screening, in my
opinion, might be okay, although it is actually
excessive, but overtreatment is not. I have read that
the survival rate for thyroid cancer is nearly 100 %, so
its treatment might be quite simple, making
thyroidectomy excessive. I suspect that the main
reason why doctors perform [complete] thyroidectomy
is because they lack the surgical skills needed to
preserve the thyroid. I will continue to undergo
screening, but seeking treatment is another issue.
Should any symptoms become serious, I would then
seek treatment; otherwise, I would want to consider
other options to manage it.”
“Ten years ago, my doctors recommended a total
thyroidectomy to prevent metastasis, but now I regret.
I was not able to get information through internet at
that time. Now, I think the surgery was unwarranted,
and I regret it.”
“Doctors recklessly provide thyroid cancer surgery for
their own financial benefit. My sisters, who have
already been diagnosed with thyroid cancer, do not
recommend thyroid cancer screening.”
“I want doctors to set guidelines through discussion. It
is time that they express sincerity.”
(d) Trust in physicians: Although some participants
expressed confusion about overdiagnosis, 27 % of
women still conveyed trust in their doctors. The
participants believed that their physicians would
rightly determine whether thyroid cancer screening
was needed or not, because they are experts. This
was particular apparent among Group 3
participants.
“I do not want to be suspicious of doctors who screen
and treat disease.”
“The press tends to exaggerate facts. We need to trust
doctors and their decisions.”
“Doctors know more about disease than laypeople. So,
if screening is recommended by my doctor, then I will
undergo the test.”
(e) Indifference: Overall, 14 % of the participants
showed a lack of concern for thyroid cancer and
overdiagnosis. This was particular apparent among
Group 1 and Group 2 women.
“I have come across related material on TV, but I just
skip it because I have no interest in it.”
“I have not heard and do not know anything about
these. I haven’t even tried to get any information on
them.”
Impact on screening decisions
After providing the information of overdiagnosis, we asked
whether the participants would continue to undergo thy-
roid cancer screening in the future or not. While responses
varied, 93 % of the participants were willing to adhere to
screening. Participants who were already diagnosed with
thyroid cancer or who were undergoing regular check-ups
for their benign nodules responded that they would con-
tinue to undergo screening and would recommend it to
others.
“Definitely, I will continue to undergo thyroid cancer
screening. The cost of screening is inexpensive. Because
all diseases have a possibility to become a threat to
my life, I myself will go on with thyroid cancer
screening, regardless of the debate surrounding it.”
“Overtreatment is a problem, but not overdiagnosis. I
will just go ahead with screening.”
“Screening should be continued. Thyroid cancer is still
a cancer, and screening is required for prevention, no
matter how big or small the cancer is.”
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“As one who has been diagnosed with thyroid cancer, I
feel that screening is necessary. I heard it during
screening examination, and I also agree, that
participating in screening is better, although thyroid
cancer is slow growing, because thyroid cancer rapidly
spreads in those of younger age.”
“I think my choice to be screened was right, and if
asked, I would recommend it to others.”
Meanwhile, changing their intentions to undergo screen-
ing, 7 % of women in Group 2 responded that the harms
of thyroid cancer screening due to overdiagnosis seem to
be greater than the benefits thereof.
“No, I do not want to get thyroid cancer screening.
There is no need to screen for thyroid cancer at all. I
only need to get screening if I have symptoms;
otherwise, I do not want to do it.”
As well, women tended to rely strongly on their physi-
cians’ decisions, although they expressed a willingness to
lengthen the screening interval after consulting with
their physician.
“Every year when I undergo screening, I feel
uncertain. My doctor does not talk about quitting the
screening though… I would feel better if doctors
would tell me that it is okay to be screened every two
or three years.”
“It would be better if doctors specified when we should
start screening and follow-up intervals thereafter.
There should be clearer guidelines for thyroid cancer
screening.”
“I will not undergo screening every year, if my doctor
agrees. If there were guidelines, I would comply with
them. Actually, I am supposed to get screened this
year, but now I have no intention to after hearing
about overdiagnosis today.”
Implications of overdiagnosis information
Herein, reactions to information on overdiagnosis differed
among the participants according to group. Participants in
Group 4, who had received a thyroidectomy after being di-
agnosed with thyroid cancer, were highly interested in the
issue of overdiagnosis, and generally, despite of the possi-
bility of overdiagnosis, felt that they had received timely
and proper surgery. They added, however, that they were
not fully aware of the side effects of the surgery, and felt
disappointment in that they were not informed about
overdiagnosis prior to surgery.
“After my surgery, I gained more than 30 kg, and my
nails and hair are not the same as before. The huge
scar left by the surgery is also stressful. I often have to
go on business trips, and whenever I go abroad, I need
to get up and take pills at the specified time, which is
annoying. Had I known about overdiagnosis and the
side effects of the surgery, I would have thought about
other options. Sufficient and accurate information
about thyroid cancer and the side effects of surgery
should be provided.”
While women in Groups 2 and 3 remained confused
about overdiagnosis, they still expressed a desire to have
access to more detailed information thereon to help
guide their decisions. Group 1 participants exhibited the
lowest interest in overdiagnosis and the highest percent-
age of those who responded that it was their first time
to hear about overdiagnosis. Confused about overdiag-
nosis information, the women in Group 1 suggested that
national guidelines on an appropriate age and interval
for thyroid cancer screening should be brought forward,
as in guidelines for other types of cancer. They voiced
hope that such guidelines would become available to
help guide their decisions to undergo screening in the
future.
“Doctors should give and share well-documented
information with patients, so that laypeople might be
able to make an informed decision.”
Discussion
In this qualitative study, we noticed a lack of awareness
about the risks of overdiagnosis in thyroid cancer screen-
ing among the participants. Participants were often
shocked by information on overdiagnosis. Surprisingly,
many women expressed skepticism about the harms of
overdiagnosis, and most trusted that their physicians
would make an appropriate decision on the necessity of
screening tests. Meanwhile, some women suspected that
doctors only offered thyroid cancer screening and treat-
ments for their own financial benefit.
Although nearly all of the participants were surprised
by information on overdiagnosis, its impact on the
women’s attitudes toward screening varied. Nevertheless,
most women were unaffected by learning about the pos-
sibility of overdiagnosis and expressed a willingness to
undergo continued screening. Some, however, stated that
this information would definitely affect their decisions to
undergo screening in the future. These differences in
screening intentions seemed to be related with the
women’s previous history of thyroid cancer screening.
Women who had previously undergone thyroid cancer
screening were more likely to maintain a positive atti-
tude toward thyroid cancer screening than those who
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had not. They particularly indicated that they were more
afraid of getting cancer than overdiagnosis or overtreat-
ment. Nonetheless, concerned with the information pro-
vided, a few of these women communicated a desire to
lengthen the interval between screenings and felt that
overdiagnosis might deter them from attending future
screening all together. Despite differences in the way
that information on overdiagnosis was presented, our
findings are similar to those of a recent breast cancer
screening study [10, 11], and suggest that similar
challenges are faced among countries where screening
is offered.
The perspectives of the women who participated in
this study highlight three important insights into aware-
ness of overdiagnosis in thyroid cancer screening. First,
our participants sometimes found it difficult to under-
stand the brief explanation of overdiagnosis that we pro-
vided, suggesting a need for better ways to communicate
the importance and risks of overdiagnosis. In the current
study, women seemed to be better understand the term
“overtreatment” than “overdiagnosis.” A recent Australian
study also reported that women were more likely to use
“overtreatment” than “overdetection” [10]. Additionally, as
further evidence of confusion concerning overdiagnosis in
the present study, many women felt that screening was
extremely important for the early detection and treatment
of cancer, regardless of its likelihood of becoming malig-
nant. In similar context, one study proposed that some
pre-malignant conditions should not be labeled as cancers
or neoplasia [14]. The authors suggested that use of the
term “cancer” should be reserved for describing lesions
with a reasonable likelihood of lethal progression if left
untreated. Further, the other study also recommended that
better predictive classification of tumours is needed in
order to avoid unnecessary cancer diagnoses and subse-
quent procedures [15]. Nonetheless, further research is
needed to identify which ways would best help lay individ-
uals conceptualize overdiagnosis.
Second, many women indicated that further information
on overdiagnosis would likely not change their intentions
to undergo future screening. In general, women’s attitudes
toward cancer screening are shaped through the informa-
tion presented to them directly by screening service pro-
viders, as well as their broader experiences with public
health campaigns that promote the benefits of screening
without explaining the harms of overdiagnosis [16, 17].
Thus, one would expect that new information confound-
ing this message (i.e., information about overdiagnosis)
would not be immediately accepted and understood, as
seen in our study. Accordingly, providing balanced infor-
mation on the effectiveness of cancer screening and culti-
vating increased awareness of the harms thereof are
needed to overcome current misplaced perceptions of the
importance of cancer screening among the Korean public.
Finally, women in the present study reported that the
recommendations of physicians were most likely to in-
fluence their screening behavior. Although some women
showed distrust of physicians after hearing about infor-
mation of overdiagnosis, the majority of women wanted
to discuss this issue with their physician. In general, the
female participants believed that their physicians were
best able to determine whether thyroid cancer screening
was needed or not, because of their expertise. However,
in Korea, women are typically invited to undergo screen-
ing directly by screening centers and may attend screening
without discussing the necessity thereof with their per-
sonal physician. In fact, the majority of the participants in
the current study said that they received no explanation of
the benefits and harms of thyroid cancer screening before
they underwent the test.
This study involves a few limitations that warrant con-
sideration. As the study sample was not designed to be
statistically representative, we cannot conclude that our
findings reflect the views of the general population. Fur-
ther, individuals who were not included in the study may
have different characteristics from those who participated
in the focus group interviews. This can be a potential
source of selection bias. Thus, larger population-based
studies are needed to help elucidate female perspectives
on overdiagnosis in order to develop more effective strat-
egies with which to convey pertinent information.
Conclusion
Although early detection of cancer is proven to save lives,
in some instances it can be harmful, such as those related
with overdiagnosis. In this study, we noticed difficulties
among women who participated in this study with under-
standing the concept of overdiagnosis. Herein, overdiagno-
sis information itself had little impact on their intentions to
undergo future screening. Additionally, women in the
present study showed a strong reliance on their physicians’
recommendations, and wanted to further discuss issues
regarding overdiagnosis with their physician. More work is
needed to discover whether our findings could be general-
ized to the wider Korean population and to develop effect-
ive ways to communicate information on overdiagnosis.
Abbreviation
PTC: Papillary thyroid cancer.
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